Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dacarbazine Clear all
Completed Phase 2 Interventional Results available

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

NCT01118026
View directory record Official record
Conditions
Lymphoma
Interventions
ABVD, BEACOPP, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
55
States / cities
San Diego, California • St. Helena, California • Lewes, Delaware + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

NCT02049905
View directory record Official record
Conditions
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Interventions
Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
15 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 18, 2026, 1:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

NCT01044966
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
ITV DepoCyt + Temozolomide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

NCT00864253
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ABI-007, Dacarbazine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors

NCT00547131
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
temozolomide, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, conventional surgery, stereotactic radiosurgery
Drug · Other · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

NCT00072345
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
lomustine, temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 18, 2026, 1:36 AM EDT
Not listed Phase 2 Interventional

Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

NCT00797472
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
R-mabHD, ABVD
Drug
Lead sponsor
American Scitech International
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 18, 2026, 1:36 AM EDT
Terminated Phase 1 Interventional

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

NCT00515788
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)

NCT02272270
View directory record Official record
Conditions
Newly Diagnosed High Grade Glioma
Interventions
Minocycline with chemoradiation (temozolomide and radiation therapy)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 18, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

NCT03018288
View directory record Official record
Conditions
Glioblastoma
Interventions
Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 18, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

NCT07085338
View directory record Official record
Conditions
Neuroblastoma Recurrent
Interventions
Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Active, not recruiting Phase 2 Interventional

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

NCT01864109
View directory record Official record
Conditions
Newly Diagnosed Ewing Sarcoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Ifosfamide, Etoposide, Surgery, Radiation Therapy*, Temozolomide, Irinotecan, Mesna, Dexrazoxane, G-CSF
Drug · Device · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 40 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors

NCT00005955
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 18, 2026, 1:36 AM EDT
Recruiting Phase 1 Interventional

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NCT07027748
View directory record Official record
Conditions
Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
Interventions
Naxitamab, Irinotecan, Temozolomide, Sargramostim granulocyte-macrophage colony stimulating factor
Drug
Lead sponsor
Steven DuBois, MD
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

NCT00943826
View directory record Official record
Conditions
Glioblastoma
Interventions
Bevacizumab, Temozolomide, Radiation therapy, Placebo
Drug · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 18, 2026, 1:36 AM EDT
Terminated Not applicable Interventional Results available

Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma

NCT02039778
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
Interventions
Stem Cell Radiotherapy (ScRT) and Temozolomide
Radiation
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 18, 2026, 1:36 AM EDT
Not listed Not applicable Interventional

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

NCT00070343
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
oblimersen sodium, dacarbazine
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

NCT01534078
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 18, 2026, 1:36 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NCT05095376
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
418
States / cities
Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

NCT03907488
View directory record Official record
Conditions
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
711
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 1:36 AM EDT
Not listed Phase 1 Interventional

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

NCT01107522
View directory record Official record
Conditions
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Interventions
CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
Drug
Lead sponsor
Tactical Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
4
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 18, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

NCT00099970
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
M200 (volociximab) in Combination with Dacarbazine (DTIC)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 18, 2026, 1:36 AM EDT